The Prolactin Pathway: Production, Function, and Regulation

Prolactin is one of the most functionally versatile hormones in the human body, involved in far more than the milk production it was named for. Produced primarily by specialized cells in the anterior pituitary gland, it also arises from the uterine lining, immune cells, and other tissues, each source governed by different molecular switches. Its regulation depends on an unusual arrangement: rather than needing a signal to start secretion, prolactin-producing cells release the hormone continuously unless dopamine actively holds them back. That core inhibitory control, combined with a self-regulating feedback loop and a sprawling list of target tissues, makes prolactin’s pathway one of the more intricate circuits in endocrinology.

Where Prolactin Is Made

The pituitary gland is the dominant source. Within the anterior pituitary, a population of cells called lactotrophs accounts for most circulating prolactin. These cells rely on a transcription factor called Pit-1, which binds to a dedicated promoter region of the prolactin gene and drives its expression. Research using single-cell imaging has shown that Pit-1 doesn’t just turn the gene on; it stabilizes and prolongs the bursts of active transcription, shaping when and how much prolactin mRNA is produced at any given moment.¹ Pit-1 also works in concert with partner factors like Pitx1 and Pitx2 to fine-tune the promoter’s responsiveness to hormonal signals, including thyrotropin-releasing hormone and growth factors.²

But the pituitary is not the only factory. The prolactin gene has an alternative promoter upstream of the pituitary-specific one, and this promoter drives expression in entirely different tissues. Lymphocytes, for example, produce their own prolactin through this pathway, as do decidualized endometrial stromal cells in the uterus.³ During pregnancy, the maternal decidua synthesizes large quantities of prolactin that accumulate in the amniotic fluid, bathing the fetus in concentrations far higher than those found in the mother’s blood.⁴ This local, extrapituitary production serves functions distinct from the circulating hormone, including immune modulation at the placental interface.

Dopamine as the Master Brake

Most pituitary hormones need a hypothalamic “releasing hormone” to stimulate their secretion. Prolactin works in reverse. Lactotrophs are naturally inclined to secrete, and the hypothalamus keeps them in check by releasing dopamine into the portal blood supply that feeds the pituitary. Dopamine binds to D2 receptors on lactotrophs, suppressing both prolactin release and lactotroph proliferation.⁵ If dopamine signaling is interrupted for any reason, whether by a tumor compressing the pituitary stalk, a medication that blocks D2 receptors, or a genetic defect, prolactin levels rise quickly.

Several stimulatory signals also influence secretion. Thyrotropin-releasing hormone (TRH) is one of the best characterized; it directly triggers prolactin release from pituitary cells.⁶ This is why people with untreated hypothyroidism sometimes develop elevated prolactin: their bodies produce excess TRH to try to push the sluggish thyroid, and the TRH spills over to stimulate lactotrophs. Estrogen is another potent stimulator, which partly explains why prolactin levels run higher in women of reproductive age than in men and why pregnancy itself causes prolactin to climb.

The Short-Loop Feedback Circuit

Prolactin regulates its own production through what researchers call short-loop feedback. When circulating prolactin rises, it acts on neurons in the hypothalamus to increase dopamine production, which then travels back to the pituitary and dampens further prolactin release.⁷ Experiments using antibodies that neutralize circulating prolactin have confirmed this directly: when prolactin is blocked, hypothalamic dopamine neurons lose their stimulatory drive, proving that the hormone itself is their activating signal.⁸

This self-correcting loop is elegant but not foolproof. During breastfeeding, the suckling stimulus overrides it temporarily, allowing prolactin to stay high enough to sustain milk production. In pathological states like prolactinomas, the tumor’s autonomous secretion can overwhelm the feedback circuit, and dopamine alone cannot hold levels in check.

How Cells Respond to Prolactin

Prolactin exerts its effects by binding to the prolactin receptor (PRLR), a transmembrane protein found on dozens of cell types throughout the body. On binding, the receptor activates an intracellular signaling cascade, primarily through the JAK-STAT pathway. This involves a tyrosine kinase called JAK2, which in turn activates transcription factors that enter the nucleus and switch on target genes. Computational models of this process in pancreatic beta cells have helped clarify how PRLR signaling drives beta cell expansion during pregnancy, a process critical for handling the increased metabolic demands of gestation. When PRLR signaling fails in that context, beta cell mass falls and gestational diabetes can result.⁹

The receptor exists in multiple isoforms produced by alternative splicing, and each isoform activates somewhat different downstream pathways, providing tissue-specific responses to the same circulating hormone.¹⁰ One isoform, the intermediate human prolactin receptor (hPRLrI), has drawn attention in breast cancer research. When coexpressed with the long-form receptor, it promotes cell proliferation and anchorage-independent growth in mammary tissue, and it appears to be widely expressed in breast cancers, especially triple-negative subtypes. Its oncogenic effects appear tied to enhanced signaling through the Ras/MAPK pathway.¹¹

Mammary Gland Development and Lactation

The most familiar role for prolactin is preparing and maintaining the breast’s capacity to produce milk. During pregnancy, prolactin and progesterone together drive the formation of alveoli, the tiny sac-like structures within the breast that actually secrete milk.¹² This “alveolar switch” represents massive tissue remodeling, converting ductal epithelium into secretory lobules capable of sustaining an infant.¹³

Prolactin’s effects on the mammary gland are not limited to pregnancy. In virgin animals, it influences ductal side branching and the regression of terminal end buds through indirect mechanisms. The direct, local action on mammary epithelial cells to build alveoli kicks in specifically during pregnancy.¹⁴ When prolactin is deficient due to pituitary damage or other causes, lactation following childbirth fails entirely.¹⁵

Suppressing Fertility During Breastfeeding

Sustained high prolactin levels during breastfeeding suppress the reproductive axis through an increasingly well-understood mechanism. Prolactin inhibits kisspeptin neurons in the hypothalamus, and since kisspeptin is a critical upstream driver of gonadotropin-releasing hormone (GnRH), that suppression ripples downstream. GnRH pulses become irregular and infrequent, luteinizing hormone (LH) fails to produce its normal mid-cycle surge, and ovulation does not occur.¹⁶ This is the basis of lactational amenorrhea, the period of absent menstruation during active breastfeeding.

Experimental work in mice has confirmed the kisspeptin link: chronic prolactin treatment suppresses kisspeptin gene expression in key hypothalamic regions and prevents the expected rise in LH. During actual lactation, though, blocking prolactin with bromocriptine only partially restores kisspeptin expression, indicating that other factors beyond prolactin itself also contribute to the reproductive suppression of breastfeeding.¹⁷

Immune Modulation

Immune cells both produce and respond to prolactin, placing the hormone at an unusual junction between the endocrine and immune systems. Prolactin promotes lymphocyte proliferation, induces expression of interleukin-2 receptors, and activates enzymes central to immune cell function.¹⁸ It can trigger proinflammatory cytokine production, but paradoxically it also exerts anti-inflammatory effects in certain contexts, suggesting its immune role is context-dependent rather than simply pro- or anti-inflammatory.¹⁹

This duality has consequences in autoimmune disease. In systemic lupus erythematosus (SLE), prolactin influences the survival and activity of both T and B lymphocytes, lowers the activation threshold of normally silenced (anergic) B cells, and promotes autoantibody production, all of which worsen disease.²⁰ The female predominance of many autoimmune conditions has long been partly attributed to estrogen, but prolactin’s immunostimulatory effects and the fact that estrogen itself raises prolactin levels adds another layer to that sex difference.

Ion and Water Balance

Across vertebrate evolution, one of prolactin’s oldest conserved roles is regulating ion and water transport. In fish, prolactin is the “freshwater-adapting hormone,” promoting ion retention and water secretion across gills, kidneys, and gut to keep internal salt levels stable in a dilute environment.²¹ Different prolactin types and receptor variants evolved in fish lineages to fine-tune this osmoregulatory capacity.²²

Mammals retained a version of this function. In renal epithelial cells, prolactin activates sodium channels (ENaC) and a chloride channel, increasing ion transport across the cell layer via a cAMP-dependent signaling pathway.²³ In the mammary gland itself, prolactin drives roughly a three-fold increase in sodium absorption by epithelial cells, a process believed to help keep the sodium concentration of milk low.²⁴ So even in mammals, prolactin’s ancient osmoregulatory identity quietly persists alongside its reproductive functions.

Metabolic Effects and Adipose Tissue

Prolactin’s metabolic footprint is more nuanced than was appreciated even a decade ago. At moderate physiological levels, prolactin appears to be metabolically protective. In diet-induced obese rats, prolactin treatment improved insulin sensitivity, prevented the swelling of fat cells (adipocyte hypertrophy), and reduced inflammation in visceral fat. It also raised levels of adiponectin, a hormone associated with healthy metabolic function. Mice completely lacking the prolactin receptor, conversely, developed greater insulin resistance and glucose intolerance on a high-fat diet.²⁵

But the picture flips at very high levels. Severe hyperprolactinemia in animal models causes “whitening” of brown adipose tissue, reducing expression of key thermogenic markers and impairing the body’s capacity for heat-generating fat burning. When combined with a high-fat diet, the metabolic damage worsened further.²⁶ This U-shaped relationship, beneficial at moderate levels and harmful at extremes, mirrors how other metabolic hormones behave and complicates clinical interpretation. Mice lacking prolactin receptor also showed reduced body weight due to less abdominal fat deposition, reinforcing that prolactin has real, dose-dependent effects on energy storage.²⁷

Brain, Behavior, and Parenting

Prolactin crosses into the brain and influences neurogenesis, the birth of new neurons. Rodent studies have shown that prolactin during early pregnancy stimulates neurogenesis in the subventricular zone. When this process is disrupted by low prolactin, postpartum anxiety increases and maternal behavior deteriorates markedly.²⁸ The implication is that prolactin’s rise in pregnancy is not just preparing the body for lactation but also priming the brain for the behavioral demands of parenthood.

Fathers are not excluded from this circuit. Clinical studies report that prolactin levels rise in new fathers as well, and elevated paternal prolactin is associated with child-caring behavior and a decreased libido, potentially shifting the father’s motivational balance from mating toward caregiving.²⁹

Hyperprolactinemia and Bone Loss

When prolactin stays persistently elevated outside of pregnancy and breastfeeding, the consequences compound over time. The most common pathological cause is a prolactinoma, a benign pituitary adenoma arising from lactotrophs. Genetic studies have identified specific molecular events in these tumors, including rearrangement and amplification of the HMGA2 gene and gain-of-function mutations found in a subset of patients.³⁰

One of the more insidious consequences of chronic hyperprolactinemia is bone loss. Elevated prolactin suppresses GnRH, which lowers sex hormones, and that hypogonadal state erodes bone density over months and years. There also appear to be direct effects of prolactin on bone cells, suppressing formation and promoting resorption.³¹ In one study of 20 men with hyperprolactinemia, lumbar spine bone density was dramatically lower than in controls, and markers of bone breakdown were elevated while markers of bone formation were suppressed. After 18 months of dopamine agonist treatment, bone density improved modestly but had not fully normalized.³² Women of childbearing age with hyperprolactinemia face similar risks because the resulting amenorrhea mimics a premature estrogen-deficient state.³³

Dopamine Agonist Therapy and Resistance

Because dopamine is the natural brake on prolactin secretion, the first-line treatment for prolactinomas and other causes of pathological hyperprolactinemia is a dopamine agonist, typically cabergoline or bromocriptine. These drugs mimic dopamine at D2 receptors on lactotrophs, suppressing both hormone output and, in most cases, shrinking the tumor itself. In the majority of patients, dopamine agonists work well.

A minority of patients, however, show resistance. Research has found that resistant prolactinomas express less D2 receptor mRNA compared to responsive ones, which may partly explain why the drug cannot gain enough traction. The ratio of long-to-short D2 receptor isoforms also appears altered in resistant tumors, though the literature contains conflicting findings on which direction the ratio shifts.³⁴ Estrogen receptors may also play a role in both the formation and drug sensitivity of these tumors, adding yet another variable to treatment response.

The Macroprolactin Trap

A diagnostic pitfall worth understanding is macroprolactin, a form of prolactin bound to immunoglobulin antibodies that creates large complexes in the blood. Standard blood tests cannot distinguish macroprolactin from biologically active monomeric prolactin, so a person with abundant macroprolactin can appear to have dangerously high prolactin levels on paper while being clinically normal. Before laboratories began routinely screening for macroprolactin, this led to frequent misdiagnosis, unnecessary imaging, and inappropriate treatment with dopamine agonists.³⁵ Modern labs use a precipitation step to separate macroprolactin from monomeric forms, but the test is not always performed automatically, so clinicians evaluating an unexpectedly high prolactin level should ensure macroprolactin has been excluded before initiating treatment.

How Scientists Came to Recognize Human Prolactin

Prolactin was identified in sheep, cows, and birds in the early 1930s, but the human form eluded researchers for decades. Most endocrinologists before 1970 doubted it even existed as a distinct hormone in humans, because attempts to purify it from pituitary tissue invariably yielded only growth hormone. The two proteins are structurally similar enough that the biochemical tools of the mid-twentieth century could not tell them apart. It took immunological methods capable of distinguishing the two hormones to finally isolate and confirm human prolactin as a separate molecule.³⁶ That breakthrough, in the early 1970s, opened up the entire field of clinical prolactin research, from understanding galactorrhea to treating prolactinomas, and retroactively explained a number of clinical phenomena that had puzzled physicians for years.